Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
NCT02243007
Terminated
This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma
Register for Updates
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
NCT00096291
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery. PURPOSE: This randomized phase II trial is comparing two different regimens of doxorubicin and paclitaxel to see how well they work in treating women who are undergoing surgery for breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
04/07/2017
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
NCT00482391
Completed
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/06/2017
Locations: Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
NCT00691054
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with locally advanced or metastatic pancreatic cancer that did not respond to first-line therapy with gemcitabine.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/04/2017
Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida +1 locations
Conditions: Pancreatic Cancer
Register for Updates
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
NCT01297452
Completed
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Solid Tumors
Register for Updates
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
NCT01090128
Terminated
The purpose of this clinical trial is to test whether treatment of patients with breast cancer with the combination of Abraxane (nab-paclitaxel), Adriamycin (doxorubicin), and Cyclophosphamide prior to surgery is safe and results in good tumor response. Up to 24 patients may be enrolled in this study at the Mitchell Cancer Institute. All patients enrolling in this study will receive treatment with the combination of Abraxane, Adriamycin, and Cyclophosphamide.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/29/2017
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Stages II-III Breast Cancer
Register for Updates
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
NCT02276560
Terminated
The purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at the time of surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2017
Locations: Moffitt Cancer Center, Tampa, Florida +8 locations
Conditions: Stage IIIA Non-Small Cell Lung Cancer
Register for Updates
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00408460
Completed
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with pac... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
03/13/2017
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico +1 locations
Conditions: Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00976573
Completed
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block the ability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2017
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +309 locations
Conditions: Melanoma (Skin)
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
NCT00662129
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherap... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2017
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +91 locations
Conditions: Breast Cancer
Register for Updates
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
NCT00618826
Completed
The purpose of this study is to look at a new chemotherapy schedule in metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2017
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Metastatic Breast Cancer
Register for Updates
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00874107
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with bevacizumab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2017
Locations: Highlands Oncology Group, Fayetteville, Arkansas +9 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates